Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (APYX) delivers innovative plasma-based energy systems for surgical and cosmetic applications. This news hub provides investors and medical professionals with timely updates on regulatory developments, product innovations, and strategic partnerships driving advancements in electrosurgical technology.
Access authoritative reporting on APYX's Advanced Energy segment developments, including Renuvion® system enhancements, and OEM manufacturing collaborations. Track financial performance updates, clinical study results, and market expansion initiatives critical to evaluating the company's position in medical device innovation.
Our curated news collection features earnings announcements, FDA clearances, research publications, and executive leadership changes. Stay informed about helium plasma technology applications in dermatology and general surgery through verified sources, maintained for accuracy and relevance.
Bookmark this page for streamlined access to APYX's evolving corporate narrative. Combine real-time updates with historical context to better understand this pioneer in energy-based surgical solutions.
Apyx Medical Corporation (NASDAQ:APYX) will release its financial results for Q3 FY2021 on November 11, 2021, after market closure. The Company specializes in medical devices using its Helium Plasma Technology, marketed as Renuvion® and J-Plasma®. A conference call will be held at 5:00 p.m. ET the same day to discuss these results. The call can be accessed by phone or via a live webcast. A telephonic replay will be available post-call. Apyx aims to enhance surgical precision and minimize tissue trauma with its innovative technology.
Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technologies, will participate in the Colliers Securities 2021 Institutional Investor Conference on September 9th, 2021. The event will be held virtually with management engaging in one-on-one meetings. Apyx is recognized for its innovative Helium Plasma Technology, marketed as Renuvion® in cosmetic surgery and J-Plasma® in the surgical market. These technologies enable precise tissue heating for enhanced surgical outcomes. For more details, visit www.ApyxMedical.com.
Apyx Medical Corporation (NASDAQ:APYX) has appointed Wendy Levine to its Board of Directors, effective August 25, 2021. Ms. Levine brings over 25 years of experience in healthcare marketing and advertising, having held leadership roles across various global healthcare companies including Johnson & Johnson and Novartis. CEO Charlie Goodwin expressed confidence in Ms. Levine's ability to enhance consumer marketing strategies for Apyx's innovative Helium Plasma Technology, marketed as Renuvion® and J-Plasma® in their respective markets.
Apyx Medical Corporation (NASDAQ:APYX) reported Q2 2021 financial results, showing significant growth with total revenue of $11.2 million, up 161% year-over-year. Advanced Energy revenue reached $10.0 million, surging 248%. Despite a net loss of $4.0 million, an improvement from $4.7 million in Q2 2020, the adjusted EBITDA loss narrowed to $2.4 million. The company updated its 2021 revenue outlook, projecting total revenue of $40.6 million to $42.6 million, reflecting 46% to 54% growth year-over-year.
Apyx Medical Corporation (NASDAQ:APYX) is set to release its financial results for Q2 2021 on August 12th, prior to the market opening. A conference call will be held at 8:00 a.m. ET on the same day to discuss the results and answer questions. Interested parties can listen by calling the provided numbers or accessing the live webcast through the Company’s website. Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Technology, which offers innovative solutions in cosmetic and surgical markets.
Apyx Medical Corporation (NASDAQ:APYX) announced participation in the JMP Securities Life Sciences Conference on June 16-17, where management will engage in a fireside chat on June 16 at 10:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through the company’s investor relations website, with an archive available post-conference. Apyx Medical specializes in Helium Plasma Technology, marketed as Renuvion® and J-Plasma®, which offers innovative solutions for cosmetic and surgical markets.
Apyx Medical Corporation (NASDAQ:APYX) has submitted a 510(k) premarket notification to the FDA seeking a specific clinical indication for its Renuvion device in dermal resurfacing procedures. This submission follows the recent completion of a U.S. IDE clinical study and signifies a crucial milestone for the company in expanding its market potential. CEO Charlie Goodwin noted the team's efforts in achieving this progress and expressed optimism regarding the FDA's review process.
Apyx Medical Corporation (NASDAQ:APYX) reported a significant increase in total revenue for Q1 2021, reaching $8.6 million, a 72.9% rise YoY. Advanced Energy revenue surged 92.2% to $7.7 million, while OEM revenue dipped 3.3% to $1.0 million. The company posted a net loss of $4.9 million, greater than the $2.0 million loss from Q1 2020. Cash reserves stood at $39.5 million. Full-year guidance was raised, projecting total revenue between $37.6 million and $39.7 million, a 36% to 43% growth from 2020.
Apyx Medical Corporation (NASDAQ:APYX) will release its financial results for Q1 2021 on May 12 before the market opens. A conference call is scheduled for 8:00 a.m. ET on the same day, where management will discuss the quarter's results and address questions. Interested listeners can join via phone or access the live webcast on the Company’s website. A telephonic replay of the call will be available shortly after, until May 21. Apyx Medical Corporation is known for its innovative Helium Plasma Technology, marketed as Renuvion® and J-Plasma®, in cosmetic and surgical markets.
Apyx Medical Corporation (NASDAQ:APYX) reported a strong fourth quarter for 2020 with total revenue of $11.5 million, up 36.8% year-over-year. Advanced Energy revenue increased 44.0% to $9.9 million. The net loss narrowed to $1.5 million from $5.4 million a year earlier. However, full-year revenue fell 1.9% to $27.7 million. The company forecasts 2021 revenue of $36.7 million to $38.7 million, projecting 32% to 40% growth, led by Advanced Energy growth of 45% to 55%.
